Skip to main content
Top
Published in: Familial Cancer 1/2019

Open Access 01-01-2019 | Original Article

Cholesterol profile in women with premature menopause after risk reducing salpingo-oophorectomy

Authors: Natalia Teixeira, Marian J. Mourits, Jan C. Oosterwijk, Ingrid E. Fakkert, Anthony R. Absalom, Stephan J. L. Bakker, Peter van der Meer, Geertruida H. de Bock

Published in: Familial Cancer | Issue 1/2019

Login to get access

Abstract

This cross-sectional study aimed to investigate the effect of premenopausal risk reducing salpingo-oophorectomy (RRSO) on the cholesterol profile of women at increased ovarian cancer risk and to assess possible effects of age at and time since RRSO. We included 207 women who underwent RRSO before menopausal age (52 years) attending the family cancer clinic of an academic hospital and 828 age-matched women from a general population cohort (PREVEND). Participants filled out a questionnaire on socio-demographic characteristics, lifestyle and medical history, had anthropometric measurements and provided blood samples for assessment of serum levels of total cholesterol, HDL-cholesterol and non-HDL-cholesterol. The correlation between RRSO and cholesterol profile was assessed with logistic regression. Furthermore, subgroup analyses were performed to explore a possible effect of age at and time since RRSO. At a median time of 5.9 years (range 2.3–25.2) after surgery, RRSO was associated with low (< 60 mg/dl) HDL-cholesterol (OR 9.74, 95% CI 5.19–18.26) and high (≥ 160 mg/dl) non-HDL-cholesterol (OR 1.85, 95% CI 1.21–2.82) when adjusting for body mass index, hormone therapy, participation on sports and previous chemotherapy. The observed association was not dependent on age or time since RRSO. The RRSO group had less smokers (19.3 vs. 25.8%) and more participation on sports (45.4 vs. 22.0%). Our results suggest that RRSO is associated with a more atherogenic cholesterol profile, despite a lower prevalence of smoking and higher prevalence of participation on sports as compared to controls. This observation can be useful for physicians involved in the counselling and follow-up of women having RRSO.
Literature
1.
go back to reference Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616–1622CrossRef Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616–1622CrossRef
2.
go back to reference Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101:80–87CrossRefPubMedPubMedCentral Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101:80–87CrossRefPubMedPubMedCentral
3.
4.
go back to reference Carr MC (2003) The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 88:2404–2411CrossRef Carr MC (2003) The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 88:2404–2411CrossRef
5.
go back to reference Anagnostis P, Stevenson JC, Crook D, Johnston DG, Godsland IF (2015) Effects of menopause, gender and age on lipids and high-density lipoprotein cholesterol subfractions. Maturitas 81:62–68CrossRefPubMed Anagnostis P, Stevenson JC, Crook D, Johnston DG, Godsland IF (2015) Effects of menopause, gender and age on lipids and high-density lipoprotein cholesterol subfractions. Maturitas 81:62–68CrossRefPubMed
6.
go back to reference Matthews KA, Crawford SL, Chae CU et al (2009) Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol 54:2366–2373CrossRefPubMedPubMedCentral Matthews KA, Crawford SL, Chae CU et al (2009) Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol 54:2366–2373CrossRefPubMedPubMedCentral
7.
go back to reference Cifkova R, Krajcoviechova A (2015) Dyslipidemia and cardiovascular disease in women. Curr Cardiol Rep 17:52CrossRef Cifkova R, Krajcoviechova A (2015) Dyslipidemia and cardiovascular disease in women. Curr Cardiol Rep 17:52CrossRef
8.
go back to reference Barton M (2013) Cholesterol and atherosclerosis: modulation by oestrogen. Curr Opin Lipidol 24:214–220CrossRefPubMed Barton M (2013) Cholesterol and atherosclerosis: modulation by oestrogen. Curr Opin Lipidol 24:214–220CrossRefPubMed
9.
go back to reference Robinson JG, Wang S, Smith BJ, Jacobson TA (2009) Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 53:316–322CrossRefPubMed Robinson JG, Wang S, Smith BJ, Jacobson TA (2009) Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 53:316–322CrossRefPubMed
10.
go back to reference Fogle RH, Stanczyk FZ, Zhang X, Paulson RJ (2007) Ovarian androgen production in postmenopausal women. J Clin Endocrinol Metab 92:3040–3043CrossRefPubMed Fogle RH, Stanczyk FZ, Zhang X, Paulson RJ (2007) Ovarian androgen production in postmenopausal women. J Clin Endocrinol Metab 92:3040–3043CrossRefPubMed
11.
go back to reference Cohen JV, Chiel L, Boghossian L et al (2012) Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy. Fam Cancer 11:69–75CrossRefPubMed Cohen JV, Chiel L, Boghossian L et al (2012) Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy. Fam Cancer 11:69–75CrossRefPubMed
12.
go back to reference Akahoshi M, Soda M, Nakashima E, Shimaoka K, Seto S, Yano K (1996) Effects of menopause on trends of serum cholesterol, blood pressure, and body mass index. Circulation 94:61–66CrossRefPubMed Akahoshi M, Soda M, Nakashima E, Shimaoka K, Seto S, Yano K (1996) Effects of menopause on trends of serum cholesterol, blood pressure, and body mass index. Circulation 94:61–66CrossRefPubMed
13.
go back to reference Dorum A, Tonstad S, Liavaag AH, Michelsen TM, Hildrum B, Dahl AA (2008) Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: a controlled, population-based study (HUNT-2). Gynecol Oncol 109:377–383CrossRefPubMed Dorum A, Tonstad S, Liavaag AH, Michelsen TM, Hildrum B, Dahl AA (2008) Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: a controlled, population-based study (HUNT-2). Gynecol Oncol 109:377–383CrossRefPubMed
14.
go back to reference Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT (2006) Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 13:265–279CrossRefPubMed Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT (2006) Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 13:265–279CrossRefPubMed
16.
go back to reference Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH (1987) Menopause and the risk of coronary heart disease in women. N Engl J Med 316:1105–1110CrossRefPubMed Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH (1987) Menopause and the risk of coronary heart disease in women. N Engl J Med 316:1105–1110CrossRefPubMed
17.
18.
go back to reference Michelsen TM, Pripp AH, Tonstad S, Trope CG, Dorum A (2009) Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study. Eur J Cancer 45:82–89CrossRefPubMed Michelsen TM, Pripp AH, Tonstad S, Trope CG, Dorum A (2009) Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study. Eur J Cancer 45:82–89CrossRefPubMed
19.
go back to reference Michelsen TM, Tonstad S, Pripp AH, Trope CG, Dorum A (2010) Coronary heart disease risk profile in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer. Int J Gynecol Cancer 20:233–239CrossRefPubMed Michelsen TM, Tonstad S, Pripp AH, Trope CG, Dorum A (2010) Coronary heart disease risk profile in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer. Int J Gynecol Cancer 20:233–239CrossRefPubMed
20.
go back to reference van Disseldorp J, Faddy MJ, Themmen AP et al (2008) Relationship of serum antimullerian hormone concentration to age at menopause. J Clin Endocrinol Metab 93:2129–2134CrossRefPubMed van Disseldorp J, Faddy MJ, Themmen AP et al (2008) Relationship of serum antimullerian hormone concentration to age at menopause. J Clin Endocrinol Metab 93:2129–2134CrossRefPubMed
21.
go back to reference Fakkert IE, van der Veer E, Abma EM et al (2017) Elevated bone turnover markers after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer. PLoS ONE 12:e0169673CrossRefPubMedPubMedCentral Fakkert IE, van der Veer E, Abma EM et al (2017) Elevated bone turnover markers after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer. PLoS ONE 12:e0169673CrossRefPubMedPubMedCentral
22.
go back to reference Fakkert IE, Abma EM, Westrik IG et al (2015) Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer. Eur J Cancer 51:400–408CrossRefPubMed Fakkert IE, Abma EM, Westrik IG et al (2015) Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer. Eur J Cancer 51:400–408CrossRefPubMed
23.
go back to reference Diercks GF, van Boven AJ, Hillege HL et al (2000) Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities in a large non-diabetic population. The PREVEND (Prevention of REnal and Vascular ENdstage Disease) study. Eur Heart J 21:1922–1927CrossRefPubMed Diercks GF, van Boven AJ, Hillege HL et al (2000) Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities in a large non-diabetic population. The PREVEND (Prevention of REnal and Vascular ENdstage Disease) study. Eur Heart J 21:1922–1927CrossRefPubMed
24.
go back to reference Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N et al (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302:1993–2000CrossRef Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N et al (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302:1993–2000CrossRef
25.
go back to reference D’Agostino RBS, Vasan RS, Pencina MJ et al (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117:743–753CrossRef D’Agostino RBS, Vasan RS, Pencina MJ et al (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117:743–753CrossRef
26.
go back to reference Conroy RM, Pyorala K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987–1003CrossRefPubMed Conroy RM, Pyorala K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987–1003CrossRefPubMed
27.
go back to reference Lokkegaard E, Jovanovic Z, Heitmann BL, Keiding N, Ottesen B, Pedersen AT (2006) The association between early menopause and risk of ischaemic heart disease: influence of Hormone Therapy. Maturitas 53:226–233CrossRefPubMed Lokkegaard E, Jovanovic Z, Heitmann BL, Keiding N, Ottesen B, Pedersen AT (2006) The association between early menopause and risk of ischaemic heart disease: influence of Hormone Therapy. Maturitas 53:226–233CrossRefPubMed
28.
go back to reference Sarrel PM, Sullivan SD, Nelson LM (2016) Hormone replacement therapy in young women with surgical primary ovarian insufficiency. Fertil Steril 106:1580–1587CrossRefPubMedPubMedCentral Sarrel PM, Sullivan SD, Nelson LM (2016) Hormone replacement therapy in young women with surgical primary ovarian insufficiency. Fertil Steril 106:1580–1587CrossRefPubMedPubMedCentral
29.
go back to reference Nordestgaard BG, Langsted A, Mora S et al (2016) Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 37:1944–1958CrossRefPubMedPubMedCentral Nordestgaard BG, Langsted A, Mora S et al (2016) Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 37:1944–1958CrossRefPubMedPubMedCentral
30.
go back to reference Mora S (2016) Nonfasting for routine lipid testing: from evidence to action. JAMA Intern Med 176:1005–1006CrossRefPubMed Mora S (2016) Nonfasting for routine lipid testing: from evidence to action. JAMA Intern Med 176:1005–1006CrossRefPubMed
31.
go back to reference Gadea E, Thivat E, Planchat E, Morio B, Durando X (2012) Importance of metabolic changes induced by chemotherapy on prognosis of early-stage breast cancer patients: a review of potential mechanisms. Obes Rev 13:368–380CrossRefPubMed Gadea E, Thivat E, Planchat E, Morio B, Durando X (2012) Importance of metabolic changes induced by chemotherapy on prognosis of early-stage breast cancer patients: a review of potential mechanisms. Obes Rev 13:368–380CrossRefPubMed
32.
go back to reference Meinardi MT, Gietema JA, van Veldhuisen DJ, van der Graaf WT, de Vries EG, Sleijfer DT (2000) Long-term chemotherapy-related cardiovascular morbidity. Cancer Treat Rev 26:429–447CrossRefPubMed Meinardi MT, Gietema JA, van Veldhuisen DJ, van der Graaf WT, de Vries EG, Sleijfer DT (2000) Long-term chemotherapy-related cardiovascular morbidity. Cancer Treat Rev 26:429–447CrossRefPubMed
Metadata
Title
Cholesterol profile in women with premature menopause after risk reducing salpingo-oophorectomy
Authors
Natalia Teixeira
Marian J. Mourits
Jan C. Oosterwijk
Ingrid E. Fakkert
Anthony R. Absalom
Stephan J. L. Bakker
Peter van der Meer
Geertruida H. de Bock
Publication date
01-01-2019
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2019
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-018-0091-5

Other articles of this Issue 1/2019

Familial Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine